Cover Image
市場調查報告書

癌症免疫概要

Immuno-Oncology Overview

出版商 Datamonitor Healthcare 商品編碼 342050
出版日期 內容資訊 英文 133 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫概要 Immuno-Oncology Overview
出版日期: 2017年12月13日 內容資訊: 英文 133 Pages
簡介

癌症免疫,是癌症研究最有希望且成長快速的領域之一,也成為授權契約、收購相關最活躍的領域之一。

本報告以癌症免疫及各種癌症免疫級為主題,提供3位關鍵意見領袖的採訪、 BioMedTracker的開發平台資料,Pharma & MedTech Business Intelligence 及 Medtrack的契約資訊等。

目錄

  • 癌症免疫概要
  • 採訪
  • CTLA-4
  • PD-1/PD-L1
  • TIM3
  • LAG3
  • OX40
  • CD40
  • CAR-T 細胞療法
  • T-細胞受體遺傳基因療法
  • 樹狀細胞療法
  • CSF1R
  • IDO
  • CEA

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0139837

Description

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions.

Highlights

The PD-1/PD-L1 inhibitor and TCR/CAR-T therapy drug classes lead development of all immuno-oncology drugs. However, several novel mechanisms of action are also in early-phase development.

Developers of approved PD-1/PD-L1 inhibitors - Bristol-Myers Squibb, Merck & Co, Roche, AstraZeneca, and Pfizer - currently dominate the immuno-oncology field in terms of the number of ongoing, conducted, and planned trials.

Furthermore, PD-1/PD-L1 inhibitors remain a focal point of immuno-oncology combinations, with various types of combination approaches being studied.

Methodology

Three key opinion leaders were interviewed for this analysis, with the full interviews being transcribed. A survey of 56 medical oncologists across the US and five major EU markets (France, Germany, Italy, Spain, and the UK) was also conducted. Pipeline data were provided by Biomedtracker and Pharmaprojects, clinical trial data were provided by Trialtrove, and deals information was provided by Strategic Transactions.

Table of contents:

8 EXECUTIVE SUMMARY

9 IMMUNO-ONCOLOGY OVERVIEW

9 Overview of the immune system and tumor cells

10 Bibliography

12 CURRENT STATUS OF IMMUNO-ONCOLOGY DEVELOPMENT

12 Immuno-oncology trials by status

12 Immuno-oncology trials by phase

13 Immuno-oncology trials by disease

14 Immuno-oncology trials by company

15 Immuno-oncology trials by mechanism of action

16 Immuno-oncology trials by country

18 PD-1/PD-L1 INHIBITORS

18 Class description

18 Clinical development of PD-1/PD-L1 inhibitors

28 Deals

32 ­Bibliography

37 CTLA-4 INHIBITORS

37 Class description

37 Clinical development of CTLA-4 inhibitors

40 Deals

41 Bibliography

42 TCR AND CAR-T THERAPIES

42 Class description

44 Clinical development of TCR and CAR-T therapies

57 Deals

59 Bibliography

61 IDO INHIBITORS

61 Class description

61 Clinical development of IDO inhibitors

64 Deals

64 Bibliography

66 EMERGING DRUG CLASSES

66 CD40 agonists

67 CEA inhibitors

68 CSF1R inhibitors

71 GITR agonists

72 LAG3 inhibitors

73 OX40 agonists

74 TIGIT inhibitors

75 TIM3 inhibitors

76 VISTA inhibitors

76 Bibliography

79 BRISTOL-MYERS SQUIBB

79 Immuno-oncology portfolio

87 Deals

88 Bibliography

90 MERCK & CO

90 Immuno-oncology portfolio

95 Deals

98 Bibliography

100 ROCHE

100 Immuno-oncology portfolio

103 Deals

105 Bibliography

106 ASTRAZENECA

106 Immuno-oncology portfolio

109 Deals

110 Bibliography

111 PFIZER

111 Immuno-oncology portfolio

113 Deals

114 Bibliography

115 IMMUNO-ONCOLOGY COMBINATIONS

117 KOL SURVEY

121 KOL INTERVIEWS

121 KOL-1: anonymous US medical oncologist/hematologist

124 KOL-2: anonymous US medical oncologist

127 KOL-3: Dr David McDermott

LIST OF FIGURES

  • 10 Figure 1: Receptors and ligands involved in cell surface-mediated molecular signaling systems that control immune response
  • 12 Figure 2: Distribution of immuno-oncology trials, by trial status
  • 13 Figure 3: Phase of planned and ongoing immuno-oncology trials, by trial status
  • 14 Figure 4: Top 25 cancers/cancer sites included in immuno-oncology trials, segmented by trial phase
  • 15 Figure 5: Top 25 industry sponsors of immuno-oncology trials, segmented by trial status
  • 16 Figure 6: Top 25 mechanisms of action in immuno-oncology trials, segmented by trial status
  • 17 Figure 7: Top 25 countries hosting immuno-oncology trials, segmented by trial status
  • 18 Figure 8: PD-1 and PD-L1 inhibitors
  • 28 Figure 9: Top 10 cancers/cancer sites included in clinical trials studying PD-1/PD-L1 inhibitors, segmented by trial status
  • 28 Figure 10: Top 10 industry sponsors of trials studying PD-1/PD-L1 inhibitors, segmented by trial status
  • 40 Figure 11: Top 10 cancers/cancer sites included in clinical trials studying CTLA-4 inhibitors, segmented by trial status
  • 40 Figure 12: Top five industry sponsors of trials studying CTLA-4 inhibitors, segmented by trial status
  • 43 Figure 13: Overview of Kymriah's CAR-T technology
  • 56 Figure 14: Top 10 cancers/cancer sites included in clinical trials studying TCR/CAR-T therapies, segmented by trial status
  • 57 Figure 15: Top 10 industry sponsors of trials studying TCR/CAR-T therapies, segmented by trial status
  • 63 Figure 16: Top 10 cancers/cancer sites included in clinical trials studying IDO inhibitors, segmented by trial status
  • 64 Figure 17: Top five industry sponsors of trials studying IDO inhibitors, segmented by trial status
  • 87 Figure 18: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Bristol-Myers Squibb, segmented by trial status
  • 95 Figure 19: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Merck & Co, segmented by trial status
  • 103 Figure 20: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Roche, segmented by trial status
  • 109 Figure 21: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by AstraZeneca, segmented by trial status
  • 113 Figure 22: Top 10 cancers/cancer sites featured in trials sponsored or co-sponsored by Pfizer, segmented by trial status
  • 115 Figure 23: Number of trials testing each immuno-oncology combination approach, segmented by trial status
  • 116 Figure 24: Number of immuno-oncology combination trials featuring approved PD-1/PD-L1 inhibitors, segmented by combination type

LIST OF TABLES

  • 19 Table 1: Overview of approved and pipeline PD-1/PD-L1 inhibitors
  • 30 Table 2: Key deals related to PD-1/PD-L1 inhibitors, 2017
  • 38 Table 3: Overview of approved and pipeline CTLA-4 inhibitors
  • 41 Table 4: Key deals related to CTLA-4 inhibitors, 2017
  • 45 Table 5: Overview of approved and pipeline TCR/CAR-T therapies
  • 58 Table 6: Key deals related to TCR/CAR-T therapies, 2017
  • 62 Table 7: Overview of pipeline IDO inhibitors
  • 64 Table 8: Key deals related to IDO inhibitors, 2017
  • 67 Table 9: Overview of pipeline CD40 agonists
  • 68 Table 10: Overview of pipeline CEA inhibitors
  • 70 Table 11: Overview of pipeline CSF1R inhibitors
  • 72 Table 12: Overview of pipeline GITR agonists
  • 73 Table 13: Overview of pipeline LAG3 inhibitors
  • 74 Table 14: Overview of pipeline OX40 agonists
  • 75 Table 15: Overview of pipeline TIGIT inhibitors
  • 76 Table 16: Overview of pipeline TIM3 inhibitors
  • 76 Table 17: Overview of pipeline VISTA inhibitors
  • 80 Table 18: Overview of Bristol-Myers Squibb's immuno-oncology portfolio
  • 88 Table 19: Key deals related to Bristol-Myers Squibb, 2017
  • 91 Table 20: Overview of Merck & Co's immuno-oncology portfolio
  • 96 Table 21: Key deals related to Merck & Co, 2017
  • 101 Table 22: Overview of Roche's immuno-oncology portfolio
  • 104 Table 23: Key deals related to Roche, 2017
  • 107 Table 24: Overview of AstraZeneca's immuno-oncology portfolio
  • 110 Table 25: Key deals related to AstraZeneca, 2017
  • 112 Table 26: Overview of Pfizer's immuno-oncology portfolio
  • 114 Table 27: Key deals related to Pfizer, 2017
  • 117 Table 28: Medical oncologists included in Datamonitor Healthcare's immuno-oncology KOL survey, 2017
  • 118 Table 29: Question 1
  • 119 Table 30: Question 2
  • 119 Table 31: Question 3
  • 120 Table 32: Question 4
  • 120 Table 33: Question 5
  • 121 Table 34: Key opinion leader information
Back to Top